The latest revision (v3) of the Guidance on how to manage clinical trials during the COVID-19 pandemic was published on 28 April. This version contains key changes based also on the feedback from different stakeholders’ groups (patients’ organisations, academia and industry) before and during the drafting process.
In order to provide your Organisation with an overview of the most important elements of this Guidance and the possibility to identify aspects for additional clarification, a webinar will be organised jointly by the European Commission, the European Medicines Agency and the Clinical Trials Facilitation and Coordination Group of HMA with the participation of the drafting team members on 15 May 15.00-17.00.
You will find more information about the webinar by clicking here.
The number of participants will have to be limited for technical reasons and thus early registration is advised by sending a message to: SANTE-PHARMACEUTICALS-B4@ec.europa.eu using “Registration to the webinar on the Guidance on clinical trials during COVID-19” in the subject line.
The link to allow access to the webex conference will be shared with participants later in May. In order to make the information available for broader public, the webex will be recorded and made public on the EMA and Commission website: EUTube.
